Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Patient Who May Have Ebola Arrives in Atlanta

December 4, 2014 9:52 am | by Jeff Martin - Associated Press | News | Comments

An American health-care worker who may have been infected with the Ebola virus in West Africa has arrived at a hospital near Atlanta. Emory University Hospital spokeswoman Holly Korschun says the patient arrived around 5:45 a.m. Thursday. Read More...

TOPICS:

Vaximm Receives Positive Data from Oral Cancer Vaccine Trial

December 4, 2014 9:40 am | News | Comments

Vaximm AG, a Swiss-German biotech company focusing on oral cancer vaccines, announced follow-on data from the first clinical trial of its investigational oral T-cell vaccine VXM01. Data of a trial extension of the randomized, placebo-controlled, double-blind Phase 1 dose escalation study show that the safety profile to date is manageable.  Read More...

TOPICS:

Array Regains Rights to Cancer Drug From Novartis

December 4, 2014 9:22 am | News | Comments

Array BioPharma Inc. announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. Read more...                           

TOPICS:
Advertisement

FDA Approves Amgen's ALL Treatment

December 3, 2014 5:10 pm | News | Comments

Amgen announced that the U.S. Food and Drug Administration (FDA) has granted approval of Blincyto (blinatumomab) for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read more...

TOPICS:

Peptide Has Promise for Treating Spinal Cord Injury

December 3, 2014 4:57 pm | by Case Western Reserve University | News | Comments

Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested. Read more...

TOPICS:

Scientists Describe New Herpes Treatment Strategy

December 3, 2014 4:49 pm | News | Comments

Scientists have developed a novel treatment approach for persistent viral infections such as herpes. Read more...                                                     

TOPICS:

PET Scans Help Identify Effective TB Drugs

December 3, 2014 4:41 pm | by University of Pittsburgh | News | Comments

Sophisticated lung imaging can show whether or not a treatment drug is able to clear tuberculosis (TB) lung infection in human and macaque studies, according to researchers at the University of Pittsburgh School of Medicine and their international collaborators. Read more...          

TOPICS:

Chemo Effect on Brain Cells Identified

December 3, 2014 4:27 pm | by UNC | News | Comments

UNC School of Medicine researchers have found for the first time a biochemical mechanism that could be a cause of “chemo brain” – the neurological side effects such as memory loss, confusion, difficulty thinking, and trouble concentrating that many cancer patients experience while on chemotherapy to treat tumors in other parts of the body. Read more...

TOPICS:
Advertisement

European Drug Regulator: Novartis Flu Vaccine OK

December 3, 2014 1:52 pm | News | Comments

Europe's drug regulator said there is no proof that a flu vaccine for the elderly was linked to side effects, including deaths in Italy. Read more...                   

TOPICS:

Pregnant Women to Get Better Info from Drug Labels

December 3, 2014 1:09 pm | by Lauran Neergard - AP Medical Writer | News | Comments

The Food and Drug Administration is revamping those confusing labels on prescription drugs to make it easier to understand which are safe to use. Read more...                 

TOPICS:

MS Research Finds First Evidence of Rogue Protein

December 3, 2014 12:43 pm | News | Comments

The Surrey-led research, published in the journal Frontiers in Neurology, has identified a rogue protein in multiple sclerosis that attacks the body's central nervous system. Read more...                                                  

TOPICS:

Study: Strengthening Evidence of Connection Between Statin Use, Cataracts

December 3, 2014 12:35 pm | by Elsevier | News | Comments

Few classes of drugs have had such a transformative effect on the prevention of cardiovascular disease (CVD) as have statins, prescribed to reduce total cholesterol and low-density lipoprotein cholesterol. However, some clinicians have ongoing concerns regarding the potential for lens opacities (cataracts) as a result of statin use. Read more...

TOPICS:

Cancer Uses Abdominal Stem Cells to Fuel Growth, Metastasis

December 3, 2014 12:28 pm | News | Comments

New research from Rice University and the University of Texas MD Anderson Cancer Center shows how ovarian tumors co-opt a specific type of adult stem cell from abdominal tissues to fuel their growth. Read more...

TOPICS:

Vitamin May Prevent Noise-Induced Hearing Loss

December 3, 2014 12:20 pm | by Weill Cornell | News | Comments

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein. Read more...

TOPICS:

Researchers Study Alzheimer's Investigational Drug

December 3, 2014 12:13 pm | by University of Cincinnati | News | Comments

Researchers at the University of Cincinnati (UC) are among those who have accepted the challenge of easing the burden of Alzheimer’s disease. They are conducting a research study to assess the effect of a new investigational drug on memory and activities of daily living in people with mild to moderate Alzheimer’s. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading